The case for plant-made veterinary immunotherapeutics

Topp, Edward; Irwin, Rebecca; McAllister, Tim A.; Lessard, Martin; Joensuu, Jussi; Kolotilin, Igor; Conrad, Udo; Stöger, Eva; Mor, Tsafrir S.; Warzecha, Heribert; Hall, Jake; McLean, Michael D.; Cox, Eric; Devriendt, Bert; Potter, Andrew; Depicker, Anna; Virdi, Vikram; Holbrook, Larry A.; Doshi, Ketan; Dussault, Marike; Friendship, Robert; Yarosh, Oksana; Yoo, Han Sang; MacDonald, Jacqueline; Menassa, Rima

doi:10.1016/j.biotechadv.2016.02.007

Cited by 46 publications

(35 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This has been recognised by governments and governmental agencies, which has in turn increased commercial viability. In addition to preparedness for human health and biosecurity [47], there is also a commercial case for the production of veterinary vaccines and therapeutics [12,48]. Attention is turning to the improvement of whole plant hosts and much of this review discusses the transient modifications that can be made to improve protein expression.…”

Section: Discussionmentioning

confidence: 99%

Innovation in plant-based transient protein expression for infectious disease prevention and preparedness

Sainsbury

2020

Current Opinion in Biotechnology

View full text Add to dashboard Cite

Addressing new challenges in global health and biosecurity requires responsive and accessible platforms for the manufacture of preventative or therapeutic interventions. Transient protein expression in plants has evolved into a technology that offers a unique combination of rapid expression, inherent scalability, and flexibility in gene stacking with the capability to produce complex proteins and protein assemblies. Technical developments that have driven the progress of transient expression in plants include advanced expression systems, protein engineering and synthetic biology approaches to transiently, or stably, modify host plants. The plasticity of transient expression in plants, speed of scalability and relatively low capital costs, highlight the great potential of this technology in the future of human and animal health.Addresses

show abstract

Section: Discussionmentioning

confidence: 99%

Innovation in plant-based transient protein expression for infectious disease prevention and preparedness

Sainsbury

2020

Current Opinion in Biotechnology

View full text Add to dashboard Cite

show abstract

“…Over recent years, the use of plant systems to express recombinant viral structural proteins, with the resulting self‐assembly of VLPs, has become increasingly popular as the method is both cost‐effective and free from the risk of contaminating animal pathogens (Lomonossoff and D'Aoust, ; Rybicki, , ; Steele et al ., ; Topp et al ., ). Thuenemann et al .…”

Section: Introductionmentioning

confidence: 97%

“…Over recent years, the use of plant systems to express recombinant viral structural proteins, with the resulting selfassembly of VLPs, has become increasingly popular as the method is both cost-effective and free from the risk of contaminating animal pathogens (Lomonossoff and D'Aoust, 2016;Rybicki, 2010Rybicki, , 2014Steele et al, 2017;Topp et al, 2016). Thuenemann et al (2013) recently reported the high-level expression of fully assembled VLPs of bluetongue virus serotype 8 (BTV-8) in N. benthamiana using the pEAQ-HT plant transient expression vector system (Sainsbury et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Immunogenicity of plant‐produced African horse sickness virus‐like particles: implications for a novel vaccine

Dennis

Meyers

Guthrie

et al. 2017

Plant Biotechnology Journal

View full text Add to dashboard Cite

SummaryAfrican horse sickness (AHS) is a debilitating and often fatal viral disease affecting horses in much of Africa, caused by the dsRNA orbivirus African horse sickness virus (AHSV). Vaccination remains the single most effective weapon in combatting AHS, as there is no treatment for the disease apart from good animal husbandry. However, the only commercially available vaccine is a live‐attenuated version of the virus (LAV). The threat of outbreaks of the disease outside its endemic region and the fact that the LAV is not licensed for use elsewhere in the world, have spurred attempts to develop an alternative safer, yet cost‐effective recombinant vaccine. Here, we report the plant‐based production of a virus‐like particle (VLP) AHSV serotype five candidate vaccine by Agrobacterium tumefaciens‐mediated transient expression of all four capsid proteins in Nicotiana benthamiana using the cowpea mosaic virus‐based HyperTrans (CPMV‐HT) and associated pEAQ plant expression vector system. The production process is fast and simple, scalable, economically viable, and most importantly, guinea pig antiserum raised against the vaccine was shown to neutralize live virus in cell‐based assays. To our knowledge, this is the first report of AHSV VLPs produced in plants, which has important implications for the containment of, and fight against the spread of, this deadly disease.

show abstract

“…So, edible orally delivered, low-cost vaccines are an urgent need in the production of disease-free animals. Topp et al (2016) recently provided a general overview of efficacy, competitiveness and regulatory approval of plant-made veterinary immunotherapeutics. This manuscript is a highly comprehensive in-depth review of plant-made veterinary vaccines to control zoonotic diseases, which has not been addressed in any previous review.…”

Section: Introductionmentioning

confidence: 99%

Plant‐based oral vaccines against zoonotic and non‐zoonotic diseases

Shahid

Daniell

2016

Plant Biotechnology Journal

View full text Add to dashboard Cite

SummaryThe shared diseases between animals and humans are known as zoonotic diseases and spread infectious diseases among humans. Zoonotic diseases are not only a major burden to livestock industry but also threaten humans accounting for >60% cases of human illness. About 75% of emerging infectious diseases in humans have been reported to originate from zoonotic pathogens. Because antibiotics are frequently used to protect livestock from bacterial diseases, the development of antibiotic‐resistant strains of epidemic and zoonotic pathogens is now a major concern. Live attenuated and killed vaccines are the only option to control these infectious diseases and this approach has been used since 1890. However, major problems with this approach include high cost and injectable vaccines is impractical for >20 billion poultry animals or fish in aquaculture. Plants offer an attractive and affordable platform for vaccines against animal diseases because of their low cost, and they are free of attenuated pathogens and cold chain requirement. Therefore, several plant‐based vaccines against human and animals diseases have been developed recently that undergo clinical and regulatory approval. Plant‐based vaccines serve as ideal booster vaccines that could eliminate multiple boosters of attenuated bacteria or viruses, but requirement of injectable priming with adjuvant is a current limitation. So, new approaches like oral vaccines are needed to overcome this challenge. In this review, we discuss the progress made in plant‐based vaccines against zoonotic or other animal diseases and future challenges in advancing this field.

show abstract

The case for plant-made veterinary immunotherapeutics

Cited by 46 publications

References 97 publications

Innovation in plant-based transient protein expression for infectious disease prevention and preparedness

Innovation in plant-based transient protein expression for infectious disease prevention and preparedness

Immunogenicity of plant‐produced African horse sickness virus‐like particles: implications for a novel vaccine

Plant‐based oral vaccines against zoonotic and non‐zoonotic diseases

Contact Info

Product

Resources

About